In contrast and consistent with our study, encouraging evidence of lapatinib in combination with gemcitabine was demonstrated in a case report of a female with metastatic, HER2-overexpressing breast cancer who developed a complete clinical response for 1 year after being treated with this combination (lapatinib 1250 mg, later reduced to 1000 mg and gemcitabine 1000 mg/m2) [35]. Here, ERBB2 is linked to breast cancer.